Dereani Sara, Macor Paolo, D'Agaro Tiziana, Mezzaroba Nelly, Dal-Bo Michele, Capolla Sara, Zucchetto Antonella, Tissino Erika, Del Poeta Giovanni, Zorzet Sonia, Gattei Valter, Bomben Riccardo
Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I,R,C,C,S,, Via Franco Gallini 2, Aviano, PN, Italy.
J Hematol Oncol. 2014 Oct 23;7:79. doi: 10.1186/s13045-014-0079-z.
Recently it was reported that microRNA from the miR-17 ~ 92 family may have a key role in chronic lymphocytic leukemia (CLL). Here, we designed specific oligonucleotides to target endogenous miR-17 (antagomiR17). In-vitro administration of antagomiR17 effectively reduced miR-17 expression and the proliferation of CLL-like MEC-1 cells. When injected in-vivo in tumor generated by the MEC-1 cells in SCID mice, antagomiR17 dramatically reduced tumor growth and significantly increase survival. Altogether, our results provide the rationale for the use of antagomiR17 as a novel potential therapeutic tool in CLL and in other lymphoproliferative disorders where miR-17 has a driver role in tumor progression.
最近有报道称，来自miR-17 ~ 92家族的微小RNA可能在慢性淋巴细胞白血病（CLL）中起关键作用。在此，我们设计了特异性寡核苷酸靶向内源性miR-17（抗miR-17）。体外给予抗miR-17可有效降低miR-17表达及CLL样MEC-1细胞的增殖。当将抗miR-17注射到SCID小鼠体内由MEC-1细胞产生的肿瘤中时，抗miR-17显著降低肿瘤生长并显著延长生存期。总之，我们的结果为抗miR-17作为CLL以及其他miR-17在肿瘤进展中起驱动作用的淋巴增殖性疾病的新型潜在治疗工具提供了理论依据。
